The company has plans to launch this Vaccine by the end of 2023 after completing the required field studies and obtaining regulatory approvals
The vectored intranasal delivery platform gives us the capability for rapid product development, scale-up, easy and painless immunization during public health emergencies and pandemics
This ambitious anti-TB campaign, as part of IOCL’s CSR, aims to ensure early identification of presumptive TB and prompt diagnosis using high-sensitivity diagnostic tests at the doorstep
For anaemia control in children (0-19 years) & resolves for Call to Action in this direction
A committee of two Joint Drugs Controllers has been constituted at CDSCO to monitor the process of inspection, reporting, and subsequent action to ensure compliance to the Drugs & Cosmetics Act, 1940
Mock drills are being conducted across the country to review the preparedness for management of COVID-19
The company continue to develop this program for the WHO markets, thereby providing coverage and protection for more infants globally in time to come
The cash and debt free consideration value is €370 million.
MindRank expects to initiate a Phase I safety study in the first quarter of 2023.
Subscribe To Our Newsletter & Stay Updated
